MIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.5 million private placement (the “Offering”) with an existing stockholder of the Company, (the “Investor”).

佛罗里达州米拉马尔，2026年9月24日（环球社讯）——临床阶段生物制药公司HCW Biologics Inc.（“公司”或“HCW Biologics”）（纳斯达克股票代码：HCWB），致力于开发变革性融合免疫疗法以治疗自身免疫性疾病、癌症及衰老相关发育不良，今日宣布完成与公司现有股东（“投资者”）达成的150万美元私募配售（“本次发行”）的定价。

Pursuant to a securities purchase agreement entered into on September 23, 2026 with the Investor (the “Purchase Agreement”), the Company agreed to issue and sell an aggregate of 903,614 units (the “Units”), with each Unit consisting of (i) one pre-funded warrant (a “Pre-Funded Warrant”) to purchase one share of the Company’s common stock, par value $0.0001 per share, (“Common Stock”) and (ii) the right to receive one common stock purchase warrant (a “Common Warrant”) to purchase one share of Common Stock, and subject to, stockholder approval of the issuance thereof..

根据公司于2026年9月23日与投资者签订的证券购买协议（“购买协议”），公司同意发行并出售总计903,614个单位（“单位”），每个单位由以下部分组成：(i) 一份预付认股权证（“预付认股权证”），用于购买一股公司普通股，每股面值0.0001美元（“普通股”）；以及 (ii) 获得一份普通股购买认股权证（“普通认股权证”）的权利，用于购买一股普通股，且上述发行须获得股东批准。

In connection with the Offering, the Company will issue 903,614 Pre-Funded Warrants. Subject to stockholder approval, which the Company is obligated to seek pursuant to the terms of the Purchase Agreement, the Investor will also be entitled to receive Common Warrants to purchase up to an aggregate of 903,614 shares of Common Stock..

与本次发行相关，公司将发行903,614份预筹资权证。在获得股东批准的前提下（公司根据购买协议的条款有义务寻求该批准），投资者还有权获得认股权证，以购买总计不超过903,614股普通股。

Maxim Group LLC is acting as the sole placement agent for the Offering.

Maxim Group LLC 担任本次发行的独家配售代理。

The combined purchase price for each Unit consisting of a Pre-Funded Warrant and the right to receive one Common Warrant upon, and subject to, stockholder approval of the issuance thereof, was $1.6599 per Unit. The Pre-Funded Warrants have an exercise price of $0.0001 per share of Common Stock, are exercisable immediately and will not expire until exercised in full.

由一份预融资权证及在获得股东批准发行该等权证的前提下收取一份普通权证的权利组成的每单位，其合并购买价格为每单位1.6599美元。预融资权证的行权价格为每股普通股0.0001美元，可立即行权，且在全部行权前不会到期。

The Common Warrants will have an exercise price of $1.66 per share and will expire on the five and one half (5.5) year anniversary of their issuance. Under Nasdaq Listing Rule 5635(d), the Company is required to obtain stockholder approval before issuing the Common Warrants because the potential issuance of shares upon exercise of the Common Warrants could exceed the thresholds set forth in such rule.

普通认股权证的行权价格为每股1.66美元，并在其发行五周年半（5.5年）之际到期。根据纳斯达克上市规则第5635(d)条，公司在发行普通认股权证之前必须获得股东批准，因为行使普通认股权证时可能发行的股份数量可能会超过该规则规定的阈值。

Following receipt of stockholder approval, the Company will issue the Common Warrants to the Investor in accordance with the Purchase Agreement..

在获得股东批准后，公司将根据购买协议向投资者发行普通认股权证。

The Company intends to use the net proceeds from this Offering to continue clinical trials for HCW9302, advance its IND-enabling studies for its T-Cell Engager, HCW11-018b, and its second-generation immune checkpoint inhibitor, HCW11-040, and for general corporate purposes.

公司拟将本次发行所得款项净额用于继续开展HCW9302的临床试验，推进其T细胞衔接器HCW11-018b和第二代免疫检查点抑制剂HCW11-040的IND申报支持性研究，并用于一般企业用途。

On September 23, 2026, the Company also entered into a registration rights agreement with the Investors, pursuant to which the Company agreed to submit to the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-1 within 15 trading days of the closing of the Offering covering the resale of the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and the shares of Common Stock issuable upon exercise of the Common Warrants.

2026年9月23日，公司还与投资者签订了一份注册权协议，根据该协议，公司同意在发行完成后的15个交易日内，向美国证券交易委员会（“SEC”）提交一份S-1表格的注册声明，涵盖因行使预融资认股权证而可发行的普通股的转售，以及因行使普通认股权证而可发行的普通股。

The Company also agreed to use commercially reasonable efforts to cause the registration statement to be declared effective by the SEC within 60 days following the closing of the Offering..

本公司亦同意尽商业上合理的努力，促使美国证券交易委员会（SEC）在本次发行交割后60天内宣布注册声明生效。

The number of shares of Common Stock the Company that may be held by the Investor, including those shares issued at closing and upon the exercise of Pre-Funded Warrants from time to time in the Offering, may not exceed 9.99% of the number of shares of the Company’s Common Stock outstanding immediately after giving effect to such issuances..

投资者可持有的公司普通股股份数量（包括在交割时发行的股份以及在发行中不时行使预付权证而发行的股份）不得超过在该等发行生效后立即计算的公司已发行普通股股份总数的9.99%。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售任何此处所述证券的要约，也不构成购买任何此类证券的要约之招揽；在任何州或其他司法管辖区，若在该等州或司法管辖区的证券法下进行注册或资格认定之前，此类要约、招揽或销售属违法，则不得在这些州或司法管辖区销售这些证券。

About HCW Biologics:

关于 HCW Biologics：

HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and in doing so, improve patients’ quality of life and possibly extend longevity.

HCW Biologics Inc.（“公司”）（纳斯达克股票代码：HCWB）是一家处于临床阶段的生物制药公司，致力于开发变革性的融合免疫疗法药物，用于治疗由慢性炎症引发的疾病，包括自身免疫性疾病、癌症以及衰老相关发育不良。公司的免疫疗法代表了一类新型药物，公司认为其有潜力从根本上改变促炎性疾病和衰老相关疾病及病症（均由慢性炎症引发）的治疗方式，从而改善患者的生活质量，并可能延长寿命。

A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs. See the Company Pipeline at .

公司临床开发和融资战略的一个关键方面是专注于其业务发展计划。请参阅公司产品管线，网址为 。

https://hcwbiologics.com/pipeline

https://hcwbiologics.com/pipeline

/

/

Forward Looking Statements:

前瞻性陈述：

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, without limitation, statements regarding the completion of the Offering and the satisfaction of customary closing conditions; the anticipated use of proceeds from the Offering; the Company’s ability to obtain stockholder approval for the issuance of the Common Warrants; the anticipated issuance of the Common Warrants following receipt of stockholder approval; the anticipated filing and effectiveness of registration statements covering the shares of Common Stock issued in the Offering; and the prospective efficacy and success of the Company’s immunotherapeutic candidates and development programs.

本新闻稿中的陈述包含“前瞻性陈述”，这些陈述受重大风险和不确定性的影响。这些陈述是根据1995年美国《私人证券诉讼改革法》的“安全港”条款作出的。本新闻稿中包含的前瞻性陈述可以通过使用诸如“预期”、“预计”、“相信”、“将”、“可能”、“应当”、“估计”、“预测”、“展望”、“预报”或其他类似词语来识别，包括但不限于以下陈述：关于完成本次发行及满足惯例成交条件的陈述；对本次发行所得款项预期用途的陈述；公司获得股东对发行普通认股权证批准的能力的陈述；在获得股东批准后预期发行普通认股权证的陈述；涵盖本次发行中发行的普通股股份的注册声明的预期提交及生效情况的陈述；以及公司免疫治疗候选药物和开发项目的预期疗效和成功前景的陈述。

Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the SEC on March 31, 2026, and in other filings filed from time to time with the SEC..

此外，某些前瞻性陈述基于对未来事件的假设，而这些假设可能被证明是不准确的。导致实际结果出现差异的因素包括但不限于：在2026年3月31日向美国证券交易委员会（SEC）提交的10-K表年度报告中“风险因素”一节所述的风险和不确定性，以及不时向SEC提交的其他文件中的相关风险和不确定性。

Company Contact:

公司联系人：

Rebecca Byam

丽贝卡·拜亚姆

Chief Financial Officer

首席财务官

rebeccabyam@hcwbiologics.com

rebeccabyam@hcwbiologics.com

This press release was published by a CLEAR® Verified individual.

本新闻稿由一位经 CLEAR® 认证的个人发布。